These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39241315)

  • 1. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
    Bakaloudi DR; Talukder R; Makrakis D; Diamantopoulos L; Enright T; Leary JB; Patgunarajah U; Thomas VM; Swami U; Agarwal N; Jindal T; Koshkin VS; Brown JR; Barata P; Murgić J; Miletić M; Johnson J; Zakharia Y; Hui G; Drakaki A; Duran I; Buznego LA; Barrera RM; Castañeda DM; Rey-Cárdenas M; Castellano D; Nguyen CB; Park JJ; Alva A; McKay RR; Stewart TF; Epstein IB; Bellmunt J; Wright JL; Gupta S; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2024 Dec; 22(6):102198. PubMed ID: 39241315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Fléchon A; Morales-Barrera R; Powles T; Alva A; Özgüroğlu M; Csöszi T; Loriot Y; Rodriguez-Vida A; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Gunduz S; Mamtani R; Yu EY; Montesa Pino A; Anido U; Sendur MAN; Gravis G; Révész J; Kostorov V; Huillard O; Ma J; Rajasagi M; Vajdi A; Lunceford J; Cristescu R; Imai K; Homet Moreno B; Matsubara N
    Clin Cancer Res; 2024 Dec; 30(23):5353-5364. PubMed ID: 39475359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Hassler MR; Moedlagl V; Hindinger H; Krauter J; Klager S; Resch I; Huebner N; Yurdakul O; Ofner H; Korn SM; D'Andrea D; Gust K; Shariat SF
    Eur Urol Focus; 2024 Sep; 10(5):779-787. PubMed ID: 38161107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D
    Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.
    Stecca C; Abdeljalil O; Sridhar SS
    Clin Genitourin Cancer; 2024 Dec; 22(6):102215. PubMed ID: 39353213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    Ma LX; Titmuss E; Loree JM; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Tu D; O'Callaghan C; Chen EX
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39631846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.
    Di Mauro A; Santorsola M; Savarese G; Sirica R; Ianniello M; Cossu AM; Ceccarelli A; Sabbatino F; Bocchetti M; Carratù AC; Pentimalli F; Ferrara G; Nasti G; Caraglia M; Ottaiano A
    J Transl Med; 2024 Dec; 22(1):1107. PubMed ID: 39639373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
    Kobayashi K; Matsumoto H; Sakano S; Yamamoto M; Tsuchida M; Tei Y; Nagao K; Oba K; Kitahara S; Yano S; Yoshihiro S; Yamamoto Y; Ohmi C; Komatsu H; Misumi T; Akao J; Shiraishi K
    Clin Genitourin Cancer; 2024 Dec; 22(6):102212. PubMed ID: 39270620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.
    Grivas P; Barata P; Moon H; Gupta S; Hutson T; Sternberg CN; Brown JR; Dave V; Downey C; Shillington AC; Katzenstein HM; Kirker M; Hanson S; Liu FX; Morris V; Bhanegaonkar A; Sonpavde GP
    Clin Genitourin Cancer; 2024 Dec; 22(6):102238. PubMed ID: 39532048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
    Miller S; Jiang R; Schipper M; Fritsche LG; Strohbehn G; Wallace B; Brinzevich D; Falvello V; McMahon BH; Zamora-Resendiz R; Ramnath N; Dai X; Sankar K; Edwards DM; Allen SG; Yoo S; Crivelli S; Green MD; Bryant AK
    Lancet Oncol; 2024 Dec; 25(12):1666-1676. PubMed ID: 39551068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.
    Xu M; Wang Y; Wang K; Hao Y; Xu C; Shi L; Song Z
    Invest New Drugs; 2024 Dec; 42(6):703-715. PubMed ID: 39617778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08).
    Park K; Kim EJ; Kim JY; Kim H; Park I; Park JH; Sohn BS; Lee HJ; Jo J; Huh SJ; Lee JL
    Curr Probl Cancer; 2024 Dec; 53():101149. PubMed ID: 39312854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.
    Ji Z; Li J; Zhang S; Jia Y; Zhang J; Guo Z
    Front Immunol; 2024; 15():1480520. PubMed ID: 39664382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability.
    Fakih M; Sandhu J; Li X; Wang C
    Oncologist; 2024 Dec; 29(12):1052-1058. PubMed ID: 39321179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
    Liu H; Hong Q; Zheng S; Zhang M; Cai L
    Lung Cancer; 2024 Dec; 198():108022. PubMed ID: 39541774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors.
    Ali-Fehmi R; Krause HB; Morris RT; Wallbillich JJ; Corey L; Bandyopadhyay S; Kheil M; Elbashir L; Zaiem F; Quddus MR; Abada E; Herzog T; Karnezis AN; Antonarakis ES; Kasi PM; Wei S; Swensen J; Elliott A; Xiu J; Hechtman J; Spetzler D; Abraham J; Radovich M; Sledge G; Oberley MJ; Bryant D
    JCO Precis Oncol; 2024 Oct; 8():e2300648. PubMed ID: 39565978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.